Search Results - "Chognot, Cathy"

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study by Henry, Robert R, Prof, Lincoff, A Michael, Prof, Mudaliar, Sunder, MD, Rabbia, Michael, MA, Chognot, Cathy, PhD, Herz, Matthias, MD

“…Summary Background Despite previous reports of potential adverse cardiovascular effects of peroxisome proliferator-activated receptor (PPAR) agonists, the…”
Get full text

Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials by Derfuss, Tobias, Bermel, Robert, Lin, Chien-Ju, Hauser, Stephen L, Kappos, Ludwig, Vollmer, Timothy, Comi, Giancarlo, Giovannoni, Gavin, Hartung, Hans-Peter, Weber, Martin S, Wang, Jianmei, Jessop, Nikki, Chognot, Cathy, Craveiro, Licinio, Bar-Or, Amit

“…Patients with multiple sclerosis (PwMS) have an increased risk of infections. To characterize incidence, clinical characteristics, outcomes and risk factors of…”
Get full text

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study by Bar-Or, Amit, Calkwood, Jonathan C., Chognot, Cathy, Evershed, Joanna, Fox, Edward J., Herman, Ann, Manfrini, Marianna, McNamara, John, Robertson, Derrick S., Stokmaier, Daniela, Wendt, Jeanette K., Winthrop, Kevin L., Traboulsee, Anthony

“…OBJECTIVEThe phase IIIb A Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Participants With Relapsing Forms of Multiple Sclerosis (VELOCE)…”
Get full text

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis by Hauser, Stephen L, Kappos, Ludwig, Montalban, Xavier, Craveiro, Licinio, Chognot, Cathy, Hughes, Richard, Koendgen, Harold, Pasquarelli, Noemi, Pradhan, Ashish, Prajapati, Kalpesh, Wolinsky, Jerry S.

“…Objective To report safety of ocrelizumab (OCR) up to 7 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis…”
Get full text

10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005) by Hauser, Stephen, Kappos, Ludwig, Filippi, Massimo, Wolinsky, Jerry, Weber, Martin, Nicholas, Jacqueline, Chognot, Cathy, Schneble, Hans-Martin, Wang, Qing, Giovannoni, Gavin, Montalban, Xavier

“…Abstract only…”
Get full text

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (1812) by Hauser, Stephen L., Kappos, Ludwig, Montalban, Xavier, Chognot, Cathy, Jessop, Nikki, Pradhan, Ashish, Prajapati, Kalpesh, Wolinsky, Jerry S.

“…Abstract only…”
Get full text

Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002) by Cerqueira, Joao, Berthele, Achim, Cree, Bruce, Filippi, Massimo, Pardo, Gabriel, Pearson, Owen, Traboulsee, Anthony, Ziemssen, Tjalf, Vollmer, Timothy, Bernasconi, Corrado, Mandel, Corey, Kulyk, Inessa, Chognot, Cathy, Schneble, Hans-Martin, Prajapati, Kalpesh, Havrdova, Eva

“…Abstract only…”
Get full text

Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis (S36.002) by Stokmaier, Daniela, Winthrop, Kevin, Chognot, Cathy, Evershed, Joanna, Manfrini, Marianna, McNamara, John, Bar-Or, Amit

“…Abstract only…”
Get full text

Routine Laboratory Measures in the Controlled-Treatment Period of Phase III Ocrelizumab Trials in Relapsing and Progressive Multiple Sclerosis (P5.425) by Wolinsky, Jerry, Kappos, Ludwig, Montalban, Xavier, Chognot, Cathy, Koendgen, Harold, Li, Carrie, Pradhan, Ashish, Hauser, Stephen

“…Abstract only…”
Get full text

Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study by Knapp, Rachel, Hardtstock, Fränce, Krieger, Julia, Wilke, Thomas, Maywald, Ulf, Chognot, Cathy, Muros-Le Rouzic, Erwan, Craveiro, Licinio

“…•The risk of serious infections in MS patients varies according to MS phenotype.•Higher rates of infection were observed in older, male, and progressive…”
Get full text

Comparing the risk of serious infections in patients with and without MS: A German claims data analysis by Knapp, Rachel, Hardtstock, Fränce, Wilke, Thomas, Maywald, Ulf, Chognot, Cathy, Craveiro, Licinio, Rouzic, Erwan Muros-Le

“…•PwMS are at higher risk for serious infections than the general population.•Bacterial/parasitic and genitourinary infections in pwMS drive in-hospital…”
Get full text

Tolérance d’ocrelizumab dans la sclérose en plaques : analyse actualisée chez des patients atteints de sclérose en plaques récurrente (SEP-R) et primaire progressive (SEP-PP) by Chognot, Cathy, Hauser, Stephen L., Kappos, Ludwig, Montalban, Xavier, Incera, Élodie, Wolinsky, Jerry S.

Get full text

Tolérance d’ocrelizumab (OCR) : analyse actualisée des données de tolérance des patients atteints de sclérose en plaques récurrente (SEP-R) ou primaire progressive (SEP-PP) by Hauser, Stephen L., Kappos, Ludwig, Montalban, Xavier, Chognot, Cathy, Pradhan, Ashish, Prajapati, Kalpesh, Wolinsky, Jerry S.

“…Le suivi de la tolérance est primordial pour évaluer le bénéfice à long terme d’OCR. La tolérance et l’efficacité d’OCR ont été montrées dans la SEP-R (1 phase…”
Get full text

Effect of the dual peroxisome proliferator-activated receptor-[alpha]/[gamma] agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study by Henry, Robert R, Lincoff, A Michael, Mudaliar, Sunder, Rabbia, Michael, Chognot, Cathy, Herz, Matthias

“…Despite previous reports of potential adverse cardiovascular effects of peroxisome proliferator-activated receptor (PPAR) agonists, the promise for PPAR…”
Get full text